Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: a mediational model.
This study used the Ottawa Decision Support Framework to evaluate a model examining associations between clinical trial knowledge, attitudinal barriers to participating in clinical trials, clinical trial self-efficacy, and clinical trial preparedness among 1256 cancer patients seen for their first outpatient consultation at a cancer center. As an exploratory aim, moderator effects for gender, race/ethnicity, education, and metastatic status on associations in the model were evaluated.



. Patients completed measures of cancer clinical trial knowledge, attitudinal barriers, self-efficacy, and preparedness. Structural equation modeling (SEM) was conducted to evaluate whether self-efficacy mediated the association between knowledge and barriers with preparedness.



. The SEM explained 26% of the variance in cancer clinical trial preparedness. Self-efficacy mediated the associations between attitudinal barriers and preparedness, but self-efficacy did not mediate the knowledge-preparedness relationship.



. Findings partially support the Ottawa Decision Support Framework and suggest that assessing patients' level of self-efficacy may be just as important as evaluating their knowledge and attitudes about cancer clinical trials.
Cancer Institute of New Jersey, New Brunswick, NJ, USA (SM).
Sharon
S
Manne
Department of Psychology, Michigan State University, East Lansing, MI, USA (DK)
Deborah
D
Kashy
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA(TA)
Terrance
T
Albrecht
Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR)
Yu-Ning
YN
Wong
Department of Bioethics, Center for Ethics, Humanities & Spiritual Care, Cleveland Clinic, Cleveland, OH, USA (ALF)
Anne Lederman
AL
Flamm
Robert H.Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA (ABB)
Al B
AB
Benson
Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR)
Suzanne M
SM
Miller
Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR)
Linda
L
Fleisher
Cancer Support Community, Washington, DC, USA (JB)
Joanne
J
Buzaglo
Colorectal Cancer Coalition, Alexandria, VA, USA (NR)
Nancy
N
Roach
International Myeloma Foundation, North Hollywood, CA, USA (MK)
Michael
M
Katz
Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR)
Eric
E
Ross
Medical College of Wisconsin, Milwaukee, WI, USA (MC)
Michael
M
Collins
Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR)
David
D
Poole
Fox Chase Cancer Center, Philadelphia, PA, USA (Y-NW, SMM, LF, ER, DP, SR)
Stephanie
S
Raivitch
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA (DMM, NJM)
Dawn M
DM
Miller
University Hospitals Seidman Cancer Center, Cleveland, OH, USA (TGK, TL)
Tyler G
TG
Kinzy
University Hospitals Seidman Cancer Center, Cleveland, OH, USA (TGK, TL)
Tasnuva
T
Liu
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA (DMM, NJM)
Neal J
NJ
Meropol
D000367:Age Factors; D000368:Aged; D002986:Clinical Trials as Topic / Q000523:psychology*; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D035842:Research Subjects / Q000523:psychology*; D020377:Self Efficacy; D012737:Sex Factors
Ottawa Decision Support Framework; cancer clinical trials; cancer patients